title: Hypothalamic Prolactin Regulation of Luteinizing Hormone Secretion in the Female Rat.
abstract: Prolactin (PRL) levels increase in response to long-term antipsychotic treatment that disrupts reproductive function. Recent evidence suggests that activation of central PRL receptors (PRLR) inhibits LH secretion and in ovariectomized rats. However, the mechanisms involved, the mode of LH secretion affected and relevance to hyperprolactinemia remain unknown. We therefore investigated the contribution of central PRL/PRLR signaling to the control of estradiol-induced surges of LH and PRL and pulsatile LH secretion under basal and hyperprolactinemic conditions. First, by subjecting ovariectomized estradiol-primed rats intracerebroventricularly administered with PRL to frequent blood sampling, we demonstrated that acute activation of hypothalamic PRLR disrupts pulsatile LH secretion. Pretreatment (intracerebroventricularly) with the pure PRLR antagonist, Δ1-9-G129R-hPRL, or the γ-aminobutyric acid receptor type A antagonist, bicuculline, blocked this effect. Next, we revealed that sustained blockade of hypothalamic PRLR using Δ1-9-G129R-hPRL augmented the magnitude of LH surges induced by estradiol benzoate and progesterone treatment and suppressed the concomitant surges of PRL. Finally, we determined that acute antagonism of central PRLR is insufficient to normalize the duration of the LH pulse interval prolonged as a result of hyperprolactinemia induced by chronic exposure to the atypical antipsychotic sulpiride. These data serve as the first evidence to suggest that PRL signaling through hypothalamic PRLR inhibits pulsatile secretion of LH in a γ-aminobutyric acid receptor type A-dependent fashion and tonically restrains the magnitude of the LH surge. Furthermore, our results indicate that transient blockade of hypothalamic PRL/PRLR signaling is not an effective strategy for restoring LH pulsatility perturbed by chronic hyperprolactinemia.
authors.affiliation: Division of Women's Health (P.G., X.F.L., K.T.O.), School of Medicine, King's College London SE1 1UL, United Kingdom; and INSERM Unité 1151 (V.G.), Faculté de Médecine, Institut Necker Enfants Malades, 75993 Paris, France.
authors.forename: Pasha
authors.initials: P
authors.lastname: Grachev
authors.affiliation: Division of Women's Health (P.G., X.F.L., K.T.O.), School of Medicine, King's College London SE1 1UL, United Kingdom; and INSERM Unité 1151 (V.G.), Faculté de Médecine, Institut Necker Enfants Malades, 75993 Paris, France.
authors.forename: Xiao Feng
authors.initials: XF
authors.lastname: Li
authors.affiliation: Division of Women's Health (P.G., X.F.L., K.T.O.), School of Medicine, King's College London SE1 1UL, United Kingdom; and INSERM Unité 1151 (V.G.), Faculté de Médecine, Institut Necker Enfants Malades, 75993 Paris, France.
authors.forename: Vincent
authors.initials: V
authors.lastname: Goffin
authors.affiliation: Division of Women's Health (P.G., X.F.L., K.T.O.), School of Medicine, King's College London SE1 1UL, United Kingdom; and INSERM Unité 1151 (V.G.), Faculté de Médecine, Institut Necker Enfants Malades, 75993 Paris, France.
authors.forename: Kevin T
authors.initials: KT
authors.lastname: O'Byrne
mesh_terms: D000818:Animals; D004958:Estradiol / Q000494:pharmacology; D005260:Female; D006966:Hyperprolactinemia / Q000378:metabolism; D007031:Hypothalamus / Q000187:drug effects* / Q000378:metabolism; D007986:Luteinizing Hormone / Q000097:blood / Q000378:metabolism*; D010052:Ovariectomy; D011388:Prolactin / Q000378:metabolism / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D011981:Receptors, Prolactin / Q000378:metabolism; D012737:Sex Factors; D015398:Signal Transduction / Q000187:drug effects / Q000502:physiology
chemical_list: D011981:Receptors, Prolactin; D004958:Estradiol; D011388:Prolactin; D007986:Luteinizing Hormone